Breast and Ovarian Cancer Genomics
51 – 60 of 88
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Protein signature predicts response to neoadjuvant treatment with chemotherapy and bevacizumab in HER2-negative breast cancers
Haugen, Mads H. ; Lingjærde, Ole Christian ; Hedenfalk, Ingrid LU
; Garred, Øystein
; Borgen, Elin
; Loman, Niklas
LU
; Hatschek, Thomas
; Børresen-Dale, Anne Lise
; Naume, Bjørn
and Mills, Gordon B.
, et al.
(2021)
In JCO Precision Oncology
5.
p.286-306
- Contribution to journal › Article
-
Mark
Common Susceptibility Loci for Male Breast Cancer
Maguire, Sarah ; Olsson, Håkan LU
; Hedenfalk, Ingrid
LU
and Orr, Nick
(2021)
In Journal of the National Cancer Institute
113(4).
p.453-461
- Contribution to journal › Article
- 2020
-
Mark
PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma
Martin de la Fuente, Laura LU ; Westbom-Fremer, Sofia LU
; Arildsen, Nicolai Skovbjerg
LU
; Hartman, Linda
LU
; Malander, Susanne
LU
; Kannisto, Päivi
LU
; Måsbäck, Anna
LU
and Hedenfalk, Ingrid
LU
(2020)
In Virchows Archiv: an international journal of pathology
477(1).
p.83-91
- Contribution to journal › Article
-
Mark
Simvastatin is a potential candidate drug in ovarian clear cell carcinomas
- Contribution to journal › Article
-
Mark
SOX2 is a promising predictor of relapse and death in advanced stage high-grade serous ovarian cancer patients with residual disease after debulking surgery
Bååth, Maria LU ; Westbom-Fremer, Sofia LU
; Martin de la Fuente, Laura
LU
; Ebbesson, Anna
LU
; Davis, Juliette
; Malander, Susanne
LU
; Måsbäck, Anna
LU
; Kannisto, Päivi
LU
and Hedenfalk, Ingrid
LU
(2020)
In Molecular and Cellular Oncology
7(6).
- Contribution to journal › Article
-
Mark
A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients
Leandersson, Pia LU
; Åkesson, Anna
LU
; Hedenfalk, Ingrid
LU
; Malander, Susanne
LU
and Borgfeldt, Christer
LU
(2020)
In PLoS ONE
15(10 October).
- Contribution to journal › Article
- 2019
-
Mark
Detecting TP53 mutations in diagnostic and archival liquid-based Pap samples from ovarian cancer patients using an ultra-sensitive ddPCR method
Arildsen, Nicolai Skovbjerg LU ; Martin de la Fuente, Laura LU ; Måsbäck, Anna LU ; Malander, Susanne LU
; Forslund, Ola
LU
; Kannisto, Päivi
LU
and Hedenfalk, Ingrid
LU
(2019)
In Scientific Reports
9(1).
p.1-8
- Contribution to journal › Article
-
Mark
Extracellular lipid loading augments hypoxic paracrine signaling and promotes glioma angiogenesis and macrophage infiltration
Offer, Svenja LU ; Menard, Julien LU ; Enriquez Perez, Julio LU
; Goncalves De Oliveira, Kelin
LU
; Indira Chandran, Vineesh
LU
; Johansson, Maria C
LU
; Bång-Rudenstam, Anna
LU
; Siesjö, Peter
LU
; Ebbesson, Anna
LU
and Hedenfalk, Ingrid
LU
, et al.
(2019)
In Journal of Experimental & Clinical Cancer Research
38.
- Contribution to journal › Article
-
Mark
A targeted mass spectrometry strategy for developing proteomic biomarkers : a case study of epithelial ovarian cancer
Huttenhain, Ruth ; Choi, Meena ; Martin de la Fuente, Laura LU ; Oehl, Kathrin ; Chang, Ching-Yun ; Zimmermann, Anne-Kathrin ; Malander, Susanne LU
; Olsson, Hakan
LU
; Surinova, Silvia
and Clough, Timothy
, et al.
(2019)
In Molecular and Cellular Proteomics
18(9).
p.1836-1850
- Contribution to journal › Article
-
Mark
Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer
Sahin, Irem Durmaz LU ; Jönsson, Jenny Maria LU and Hedenfalk, Ingrid LU
(2019)
In Oncotarget
10(65).
p.6981-6996
- Contribution to journal › Article